Springboard breeds world-class ecosystem
Summary
More than HK$40 billion has been raised by companies incubated at the park including biomedical technology firms, in the past four years.Early next year, a drug safety testing center will help promising the rapeutics and medical devices to get from the pre-clinical phase to the clinical stage, Kao said. It will offer preclinical services compliant with good laboratory practice principles in areas like toxicology, safety pharmacology and reproductive toxicology.An inside view of a Biotech support lab at Hong Kong Science Park. (PHOTO PROVIDED TO CHINA DAILY)Biotech companies also benefit from the Biobank and the Biomedical Informatics Platform.Biobank, set up under global guidelines, is a central repository which processes, securely stores and distributes biospecimens for research to foster innovative discoveries and improve treatment options. Encouraged by the central governments support and the success of InnoHK research clusters, Chief Executive Carrie Lam Cheng Yuet-ngor proposed in her latest policy address the creation of an InnoLife Healthtech Hub at the Hong Kong-Shenzhen Innovation and Technology Park (HSITP) to build on the life and health sciences strengths. The government-led InnoHK research clusters, focusing on two major areas healthcare technologies, as well as AI and robotics have established the first batch of about 20 R&D centers at Hong Kong Science Park, Kao said.The regulatory framework to support the biomedical industry and to ensure treatment safety was also strengthened.